Eight European countries that include Denmark, Norway, Italy, Iceland, Estonia, Latvia, Lithuania and Luxembourg have stopped using Oxford-AstraZeneca COVID-19 vaccine as a precaution to blood clot incidents in some countries.
However, the EU medicines regulator says there is no indication that the Oxford-AstraZeneca COVID-19 vaccine is linked to an increased risk of blood clots.
Nigeria’s National Agency for Food and Drug Administration and Control approved the use of the vaccine recently.
Austria had stopped using a batch of AstraZeneca shots, as authorities continue to investigate a death from coagulation disorders and an illness from a pulmonary embolism continued
The European medicine regulator, EMA, said the vaccine’s benefits outweighed its risks and could continue to be administered.
Countries in Europe are struggling to speed up a vaccine rollout after delivery delays from Pfizer and AstraZeneca, even as a spike in cases amid a more contagious virus variant has triggered fresh lockdowns in countries like Italy and France.
After a 60-year-old woman, who was given an AstraZeneca shot from the same batch used in Austria, formed a blood clot and died, Denmark suspended the shots for two weeks.
According health authorities in the country, the response was also prompted by reports “of possible serious side effects” from other European countries.
Danish Health Minister, Magnus Heunicke wrote on Twitter, “It is currently not possible to conclude whether there is a link. We are acting early, it needs to be thoroughly investigated.”
The vaccine would be suspended for 14 days in Denmark.
The Director of Infection Prevention and Control at the Norwegian Institute of Public Health (FHI), Geir Bukholm told a news conference, “This is a cautionary decision.”
Although FHI did not say how long the suspension would last, Bukholm said, “We … await information to see if there is a link between the vaccination and this case with a blood clot.”
On Thursday Iceland suspended jabs with the vaccine as it awaited the results of an investigation by the EMA.
Italy, also on Thursday, said it would suspend use of an AstraZeneca batch different to the one used in Austria.
According some health experts, there was little evidence to suggest the AstraZeneca vaccine should not be administered and that the cases of blood clots corresponded with the rate of such cases in the general population.
“The problem with spontaneous reports of suspected adverse reactions to a vaccine are the enormous difficulty of distinguishing a causal effect from a coincidence,” Stephen Evans, professor of pharmacoepidemiology at the London School of Hygiene & Tropical Medicine, told Reuters.
Evans added that the COVID-19 disease was very strongly associated with blood clotting.
Phil Bryan, head of the UK Medicines and Healthcare Products Regulatory Agency (MHRA) said reports of blood clots so far didn’t exceed what would have occurred naturally in the vaccinated population.
“Available evidence does not confirm that the vaccine is the cause,” he said.
Reuters reports that more than 11 million doses of AstraZeneca’s vaccine have so far been administered across the UK.
AstraZeneca told Reuters in a written statement the safety of its vaccine had been extensively studied in human trials and peer-reviewed data confirmed it was generally well tolerated.
The drugmaker said this week there had been “no confirmed serious adverse events associated with the vaccine”.
It said it was in contact with Austrian authorities and would fully support their investigation.
The European Union’s drug regulator, the EMA, said on Wednesday there was no evidence so far linking AstraZeneca to the two cases in Austria.
It said the number of thromboembolic events – marked by the formation of blood clots – in people who have received the AstraZeneca vaccine was no higher than that seen in the general population, with 22 cases reported among the 3 million people who have received the shot as of March 9.
EMA said it understood the decision by Denmark and Norway was taken as a precaution.
Four other countries – Estonia, Lithuania, Luxembourg and Latvia – have stopped inoculations from the batch while investigations continue, the EMA said.
The batch of 1 million doses went to 17 EU countries.
Swedish authorities said they did not find sufficient evidence to stop vaccination with AstraZeneca’s jab.
“There is nothing to indicate that the vaccine causes this type of blood clots,” Veronica Arthurson, head of drug safety at the Swedish Medical Products Agency, told a news conference.
The Danish Medicines Agency said it had launched an investigation into the vaccine together with corresponding agencies in other EU countries and the EMA.
So far, 138,148 Danes have received a shot with AstraZeneca’s vaccine in a country of 5.8 million. The Nordic country, which also uses vaccines from Pfizer-BioNTech and Moderna, is set to receive 2.6 million doses from AstraZeneca over the coming months.
Denmark’s Health Authority said the final date for when it expects all Danes to have been fully vaccinated would be pushed back by four weeks to Aug. 15.
Spain on Thursday said it had not registered any cases of blood clots related to AstraZeneca’s vaccine so far and would continue administering the shots.
The EU’s drugs regulator on Thursday approved Johnson & Johnson’s single dose COVID-19 vaccine.